Literature DB >> 30354366

Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy.

Seung-Pyo Lee1,2, Euan A Ashley1,3,4, Julian Homburger4, Colleen Caleshu3, Eric M Green5, Daniel Jacoby6, Steven D Colan7, Edmundo Arteaga-Fernández8, Sharlene M Day9, Francesca Girolami10, Iacopo Olivotto10, Michelle Michels11, Carolyn Y Ho12, Marco V Perez1,3.   

Abstract

Background Although atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) patients, the relationship between genetic variation and AF has been poorly defined. Characterizing genetic subtypes of HCM and their associations with AF may help to improve personalized medical care. We aimed to investigate the link between sarcomeric gene variation and incident AF in HCM patients. Methods and Results Patients from the multinational Sarcomeric Human Cardiomyopathy Registry were followed for incident AF. Those with likely pathogenic or pathogenic variants in sarcomeric genes were included. The AF incidence was ascertained by review of medical records and electrocardiograms at each investigative site. One thousand forty adult HCM patients, without baseline AF and with likely pathogenic or pathogenic variation in either MYH7 (n=296), MYBPC3 (n=659), or thin filament genes (n=85), were included. Compared with patients with variation in other sarcomeric genes, those with MYH7 variants were younger on first clinical encounter at the Sarcomeric Human Cardiomyopathy Registry site and more likely to be probands than the MYBPC3 variants. During an average follow-up of 7.2 years, 198 incident AF events occurred. Patients with likely pathogenic or pathogenic mutations in MYH7 had the highest incidence of AF after adjusting for age, sex, proband status, left atrial size, maximal wall thickness, and peak pressure gradient (hazard ratio, 1.7; 95% CI, 1.1-2.6; P=0.009). Conclusions During a mean follow-up of 7.2 years, new-onset AF developed in 19% of HCM patients with sarcomeric mutations. Compared with other sarcomeric genes, patients with likely pathogenic or pathogenic variation in MYH7 had a higher rate of incident AF independent of clinical and echocardiographic factors.

Entities:  

Keywords:  atrial fibrillation; cardiomyopathy, hypertrophic; genetic variation; incidence; mutations

Mesh:

Substances:

Year:  2018        PMID: 30354366     DOI: 10.1161/CIRCHEARTFAILURE.118.005191

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  14 in total

Review 1.  Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification.

Authors:  Fergus Stafford; Kate Thomson; Alexandra Butters; Jodie Ingles
Journal:  Curr Cardiol Rep       Date:  2021-01-12       Impact factor: 2.931

Review 2.  Arrhythmias as Presentation of Genetic Cardiomyopathy.

Authors:  J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson
Journal:  Circ Res       Date:  2022-05-26       Impact factor: 23.213

3.  Partial and complete loss of myosin binding protein H-like cause cardiac conduction defects.

Authors:  David Y Barefield; Sean Yamakawa; Ibrahim Tahtah; Jordan J Sell; Michael Broman; Brigitte Laforest; Sloane Harris; Alejandro Alvarez-Arce; Kelly N Araujo; Megan J Puckelwartz; J Andrew Wasserstrom; Glenn I Fishman; Elizabeth M McNally
Journal:  J Mol Cell Cardiol       Date:  2022-05-06       Impact factor: 5.763

Review 4.  Genetic and non-genetic risk factors associated with atrial fibrillation.

Authors:  Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey
Journal:  Life Sci       Date:  2022-04-03       Impact factor: 6.780

Review 5.  Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease.

Authors:  Victoria N Parikh
Journal:  Circ Genom Precis Med       Date:  2021-02-01

Review 6.  Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.

Authors:  James A Spudich
Journal:  Pflugers Arch       Date:  2019-02-15       Impact factor: 3.657

7.  Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy.

Authors:  Lazar Velicki; Djordje G Jakovljevic; Andrej Preveden; Miodrag Golubovic; Marija Bjelobrk; Aleksandra Ilic; Snezana Stojsic; Fausto Barlocco; Maria Tafelmeier; Nduka Okwose; Milorad Tesic; Paul Brennan; Dejana Popovic; Arsen Ristic; Guy A MacGowan; Nenad Filipovic; Lars S Maier; Iacopo Olivotto
Journal:  BMC Cardiovasc Disord       Date:  2020-12-09       Impact factor: 2.298

8.  YTHDF2 alleviates cardiac hypertrophy via regulating Myh7 mRNA decoy.

Authors:  Hongfei Xu; Zhen Wang; Miao Chen; Wenting Zhao; Tingting Tao; Liang Ma; Yiming Ni; Weidong Li
Journal:  Cell Biosci       Date:  2021-07-15       Impact factor: 7.133

Review 9.  Atrial fibrillation-a complex polygenetic disease.

Authors:  Julie H Andersen; Laura Andreasen; Morten S Olesen
Journal:  Eur J Hum Genet       Date:  2020-12-05       Impact factor: 4.246

10.  Investigating gene-microRNA networks in atrial fibrillation patients with mitral valve regurgitation.

Authors:  Joana Larupa Santos; Ismael Rodríguez; Morten S Olesen; Bo Hjorth Bentzen; Nicole Schmitt
Journal:  PLoS One       Date:  2020-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.